Protara Therapeutics, Inc. (TARA) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
TARA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TARA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export TARA earnings history in CSV or JSON format
Free sign-in required to download data
Protara Therapeutics, Inc. (TARA) Earnings Overview
As of May 8, 2026, Protara Therapeutics, Inc. (TARA) reported trailing twelve-month net income of -$57M, reflecting +38.2% year-over-year growth. The company earned $-1.25 per diluted share over the past four quarters.
Looking at the long-term picture, TARA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2014.
Protara Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCKT (-$223M net income), FOLD (-$27M net income, -4.3% margin), RARE (-$609M net income, -85.4% margin), TARA has comparable earnings metrics. Compare TARA vs RCKT →
TARA Earnings vs Peers
Earnings metrics vs comparable public companies
TARA Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$57M | -28.8% | -$65M | $-1.34 | - | - |
| 2024 | -$45M | -10.3% | -$49M | $-2.17 | - | - |
| 2023 | -$40M | +38.7% | -$44M | $-3.57 | - | - |
| 2022 | -$66M | -39.6% | -$67M | $-5.86 | - | - |
| 2021 | -$47M | -39.1% | -$47M | $-4.20 | - | - |
| 2020 | -$34M | -126.6% | -$34M | $-4.70 | - | - |
| 2019 | -$15M | +41.1% | -$15M | $-3.63 | - | - |
| 2018 | -$25M | +15.1% | -$26M | $-9.93 | - | - |
| 2017 | -$30M | -5.0% | -$30M | $-69.38 | - | - |
| 2016 | -$29M | -33.4% | -$29M | $-68.90 | - | - |
See TARA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TARA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TARA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTARA — Frequently Asked Questions
Quick answers to the most common questions about buying TARA stock.
Is TARA growing earnings?
TARA EPS is $-1.25, with earnings growth accelerating to +38.2%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-57M.
What are TARA's profit margins?
Protara Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are TARA's earnings?
TARA earnings data spans 2012-2025. The accelerating earnings trend is +38.2% YoY. Historical data enables comparison across business cycles.